• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary: Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.

作者信息

Liu Yingjie, Wang Keying, Wu Wenjiang

机构信息

Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.

出版信息

Front Pharmacol. 2025 Jul 7;16:1625961. doi: 10.3389/fphar.2025.1625961. eCollection 2025.

DOI:10.3389/fphar.2025.1625961
PMID:40693265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12277752/
Abstract
摘要

相似文献

1
Commentary: Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.述评：炎症性肠病中的抗TNFα治疗：从原创药到生物类似药
Front Pharmacol. 2025 Jul 7;16:1625961. doi: 10.3389/fphar.2025.1625961. eCollection 2025.
2
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.炎症性肠病中的抗TNFα治疗：从原研药到生物类似药
Front Pharmacol. 2024 Jul 24;15:1424606. doi: 10.3389/fphar.2024.1424606. eCollection 2024.
3
Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence.生物类似药与参照生物制品在类风湿关节炎治疗起始阶段的比较有效性和安全性：真实世界证据的系统评价
Int J Clin Pharm. 2025 Jun 25. doi: 10.1007/s11096-025-01956-6.
4
[Questionnaire Survey on Adoption and Prescription of Biosimilars (Antibody and Its-related Products) by Medical Doctors in Japan].[日本医生对生物类似药（抗体及其相关产品）的采用与处方情况问卷调查]
Yakugaku Zasshi. 2022 May 1;142(5):547-560. doi: 10.1248/yakushi.21-00216. Epub 2022 Feb 22.
5
Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System.生物类似药在儿童炎症性肠病中的有效性和安全性：基于法国国家卫生数据系统的观察性纵向研究
World J Pediatr. 2025 Jan;21(1):62-72. doi: 10.1007/s12519-024-00873-4. Epub 2025 Jan 23.
6
Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.促红细胞生成素（生物类似药与原研药）在临床实践中的比较有效性和安全性：意大利一项基于人群的队列研究
BMJ Open. 2017 Mar 10;7(3):e011637. doi: 10.1136/bmjopen-2016-011637.
7
Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies.护士在帮助炎症性肠病患者过渡到生物类似药方面发挥着关键作用：教育和沟通策略。
J Crohns Colitis. 2019 Feb 1;13(2):259-266. doi: 10.1093/ecco-jcc/jjy150.
8
Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.英夫利昔单抗生物类似药治疗炎症性肠病的系统评价。
BioDrugs. 2017 Feb;31(1):37-49. doi: 10.1007/s40259-016-0206-1.
9
Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilars.肿瘤坏死因子 α 抑制剂产品上市后生产变更的性质和时间：对原研药和生物类似药的 20 年随访研究。
Eur J Pharm Sci. 2022 Aug 1;175:106227. doi: 10.1016/j.ejps.2022.106227. Epub 2022 May 27.
10
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.在类风湿关节炎和银屑病试验中，原研 TNF 抑制剂和生物类似药的疗效和安全性结局：系统文献回顾。
BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.

本文引用的文献

1
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.炎症性肠病中的抗TNFα治疗：从原研药到生物类似药
Front Pharmacol. 2024 Jul 24;15:1424606. doi: 10.3389/fphar.2024.1424606. eCollection 2024.
2
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.随机对照试验：英夫利昔单抗 CT-P13 在炎症性肠病中的皮下与静脉输注维持治疗。
Gastroenterology. 2021 Jun;160(7):2340-2353. doi: 10.1053/j.gastro.2021.02.068. Epub 2021 Mar 5.
3
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents.生物类似药治疗风湿性疾病、斑块型银屑病和炎症性肠病的免疫原性：临床试验和监管文件的综述。
BioDrugs. 2020 Feb;34(1):27-37. doi: 10.1007/s40259-019-00394-x.
4
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.抗 TNF 初治活动期腔型克罗恩病患者抗 TNF 治疗失败的预测因素：一项前瞻性、多中心、队列研究。
Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3. Epub 2019 Feb 27.
5
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.生物类似药英夫利昔单抗（CT-P13）在转换为原研药英夫利昔单抗后的长期疗效和安全性：NOR-SWITCH 试验的开放标签扩展。
J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12.
6
Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.生物类似药在炎症性肠病中的疗效、安全性和免疫原性：系统评价。
Curr Med Chem. 2019;26(2):270-279. doi: 10.2174/0929867323666161014153346.
7
Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.美国儿童和成人克罗恩病及溃疡性结肠炎的直接医疗费用。
Gastroenterology. 2008 Dec;135(6):1907-13. doi: 10.1053/j.gastro.2008.09.012. Epub 2008 Sep 17.